Jaguar Health, Inc. (JAGX) vs Moleculin Biotech, Inc. (MBRX)
A side-by-side comparison of Jaguar Health, Inc. and Moleculin Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
JAGX
Jaguar Health, Inc.
$5.85HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
MBRX
Moleculin Biotech, Inc.
$0.46HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT
Total return — JAGX vs MBRX
growth of $100 · dividends reinvested · last 9yJAGX -100.0% (-84.5%/yr)MBRX -99.9% (-52.5%/yr)MBRX compounded faster over this window
Log scale — wide-divergence pair
JAGX MBRX
JAGX vs MBRX: by the numbers
- •JAGX is the larger company ($3M vs $2M market cap).
- •Both run net losses; MBRX's is the smaller (0.00% vs -131.76% net margin).
Metrics side by side
Valuation
| Metric | JAGX | MBRX |
|---|---|---|
| P/S ratio | 0.09 | N/A |
| P/B ratio | 0.38 | 0.21 |
Profitability
| Metric | JAGX | MBRX |
|---|---|---|
| Gross margin | 67.21% | 0.00% |
| Operating margin | -391.87% | 0.00% |
| Net margin | -131.76% | 0.00% |
| ROE | -554.01% | -261.73% |
| ROIC | -110.81% | -242.25% |
Growth (annualized)
| Metric | JAGX | MBRX |
|---|---|---|
| Revenue CAGR (5Y) | 31.88% | N/A |
| Total return CAGR (5Y) | N/A | -78.48% |
Go deeper
Dig into the metrics
Jaguar Health ROEMoleculin Biotech ROEJaguar Health operating marginMoleculin Biotech operating marginJaguar Health revenue growthMoleculin Biotech revenue growthJaguar Health free cash flowMoleculin Biotech free cash flow
Jaguar Health & Moleculin Biotech appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.